Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 91.4% during the 4th quarter, HoldingsChannel reports. The firm owned 2,940 shares of the medical research company’s stock after selling 31,134 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Charles River Laboratories International were worth $695,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRL. Wetherby Asset Management Inc. raised its holdings in Charles River Laboratories International by 2.5% in the 1st quarter. Wetherby Asset Management Inc. now owns 1,793 shares of the medical research company’s stock valued at $509,000 after buying an additional 44 shares during the period. Raymond James Trust N.A. raised its holdings in Charles River Laboratories International by 4.8% in the 2nd quarter. Raymond James Trust N.A. now owns 1,117 shares of the medical research company’s stock valued at $235,000 after buying an additional 51 shares during the period. Toroso Investments LLC increased its stake in Charles River Laboratories International by 4.8% during the third quarter. Toroso Investments LLC now owns 1,141 shares of the medical research company’s stock worth $225,000 after purchasing an additional 52 shares during the period. Massmutual Trust Co. FSB ADV increased its stake in Charles River Laboratories International by 21.5% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 328 shares of the medical research company’s stock worth $78,000 after purchasing an additional 58 shares during the period. Finally, Stephens Inc. AR increased its stake in Charles River Laboratories International by 3.4% during the second quarter. Stephens Inc. AR now owns 1,831 shares of the medical research company’s stock worth $385,000 after purchasing an additional 60 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. UBS Group boosted their price target on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday, February 15th. TheStreet upgraded shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Guggenheim lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Argus boosted their price target on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Finally, Citigroup boosted their price objective on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a research report on Thursday, February 15th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $253.23.

Insider Activity at Charles River Laboratories International

In related news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at $626,155.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the sale, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at $3,437,635. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at $626,155.20. The disclosure for this sale can be found here. Insiders sold 14,932 shares of company stock valued at $3,693,663 over the last three months. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $229.90 on Thursday. The stock has a 50 day moving average price of $253.47 and a 200 day moving average price of $220.92. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $11.84 billion, a price-to-earnings ratio of 24.96, a price-to-earnings-growth ratio of 1.85 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The firm’s quarterly revenue was down 7.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.98 earnings per share. Research analysts predict that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).